Multimodality Therapy for Locally Advanced and Limited Stage IV Breast Cancer: The Impact of Effective Non-Cross-Resistant Late-Consolidation Chemotherapy’


To determine the effectiveness of non-cross-resistant late-consolidation chemotherapy in locally advanced breast cancer (LABC) and stage IV breast cancer, we review our experience with two regimens. Between 1985 and 1991, we enrolled 56 patients with LABC, who were treated with a doxorubicin-based adjuvant regimen, followed by a lateconsolidation non-cross… (More)


7 Figures and Tables